CA2319465A1 - Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees - Google Patents

Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees Download PDF

Info

Publication number
CA2319465A1
CA2319465A1 CA002319465A CA2319465A CA2319465A1 CA 2319465 A1 CA2319465 A1 CA 2319465A1 CA 002319465 A CA002319465 A CA 002319465A CA 2319465 A CA2319465 A CA 2319465A CA 2319465 A1 CA2319465 A1 CA 2319465A1
Authority
CA
Canada
Prior art keywords
compound
methyl
bis
tetrazolyl
imino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002319465A
Other languages
English (en)
Other versions
CA2319465C (fr
Inventor
Theodore J. Nitz
Daniel C. Pevear
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microdose Therapeutx Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2319465A1 publication Critical patent/CA2319465A1/fr
Application granted granted Critical
Publication of CA2319465C publication Critical patent/CA2319465C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes de prophylaxie et de traitement d'infections causées par les virus de la famille des Paramyxoviridae, et plus précisément de la sous-famille des Pneumovirinae, et de maladies associées à ces infections.
CA2319465A 1998-01-29 1999-01-29 Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees Expired - Lifetime CA2319465C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7303898P 1998-01-29 1998-01-29
US60/073,038 1998-01-29
US7307898P 1998-01-30 1998-01-30
US60/073,078 1998-01-30
PCT/US1999/001985 WO1999038508A1 (fr) 1998-01-29 1999-01-29 Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees

Publications (2)

Publication Number Publication Date
CA2319465A1 true CA2319465A1 (fr) 1999-08-05
CA2319465C CA2319465C (fr) 2013-03-19

Family

ID=26754055

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2319465A Expired - Lifetime CA2319465C (fr) 1998-01-29 1999-01-29 Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees

Country Status (9)

Country Link
EP (1) EP1051169A4 (fr)
JP (1) JP2002501894A (fr)
CN (1) CN1289248A (fr)
AU (1) AU759772B2 (fr)
BR (1) BR9908522A (fr)
CA (1) CA2319465C (fr)
MX (1) MXPA00007394A (fr)
NZ (1) NZ505894A (fr)
WO (1) WO1999038508A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489338B2 (en) 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
CA2464472C (fr) 2001-10-22 2014-01-07 The Scripps Research Institute Composes de ciblage d'anticorps
AU2003258177A1 (en) * 2002-08-09 2004-02-25 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2004014316A2 (fr) * 2002-08-09 2004-02-19 Viropharma Incorporated Composes, compositions et techniques de traitement et de prevention de l'infection par des pneumovirus et de maladies associees
CA2541618C (fr) 2003-10-30 2011-12-13 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs polymerase rsv
CA2548374C (fr) 2003-12-23 2014-05-27 Astex Therapeutics Limited Derives de pyrazole servant de modulateurs de proteine kinase
WO2006136821A1 (fr) 2005-06-22 2006-12-28 Astex Therapeutics Limited Composes pharmaceutiques
WO2006136837A2 (fr) 2005-06-23 2006-12-28 Astex Therapeutics Limited Composes pharmaceutiques
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
EP2395992A2 (fr) 2009-02-10 2011-12-21 The Scripps Research Institute Vaccination programmée chimiquement
KR20150037946A (ko) * 2012-06-29 2015-04-08 마이크로도스 테라퓨특스, 인코포레이티드 뉴모바이러스 감염 및 관련 질환을 치료하거나 예방하기 위한 조성물 및 방법
CN105793265B (zh) 2013-12-10 2018-02-13 山东丹红制药有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
EP3305790B1 (fr) 2015-06-08 2020-08-05 Shangdong Danhong Pharmaceutical Co., Ltd. Procédé de préparation d'un dérivé d'imidazole et d'un intermédiaire de celui-ci et sa forme cristalline
US20230082611A1 (en) * 2019-06-13 2023-03-16 Cidara Therapeutics, Inc. Compositions and methods for the treatment of respiratory syncytial virus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1508392A (en) * 1975-01-20 1978-04-26 Sterling Drug Inc Phenylalkanoylamines
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
US5098920A (en) * 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
CA2166100A1 (fr) * 1993-06-23 1995-01-05 Richard A. Glennon Ligands de recepteur sigma et leur emploi
AU6475696A (en) * 1995-07-27 1997-02-26 Warner-Lambert Company Substituted phenols as novel calcium channel blockers
CN1163401A (zh) * 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
PT889877E (pt) * 1996-03-29 2002-02-28 Searle & Co Derivados fenileno meta substituidos e sua utilizacao como antagonitas ou inibidores integrina alfa v beta3

Also Published As

Publication number Publication date
CA2319465C (fr) 2013-03-19
NZ505894A (en) 2002-12-20
JP2002501894A (ja) 2002-01-22
BR9908522A (pt) 2001-10-02
EP1051169A4 (fr) 2002-05-29
CN1289248A (zh) 2001-03-28
MXPA00007394A (es) 2003-08-01
AU759772B2 (en) 2003-05-01
WO1999038508A1 (fr) 1999-08-05
EP1051169A1 (fr) 2000-11-15

Similar Documents

Publication Publication Date Title
CA2319465C (fr) Composes, compositions et methodes de traitement ou de prevention d'infections pneumovirales et de maladies associees
FI91869C (fi) Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
AU2568599A (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
DK175824B1 (da) Styrylpyrazoler,-isoxazoler og analoge forbindelser farmaceutiske præparater med aktivitet mod 5-lipoxygenase eller cyclooxygenase eller............
US4788195A (en) 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
JP3028628B2 (ja) 抗炎症剤としての２−置換チアゾリジノン、オキサゾリジノンおよびイミダゾリジノンの３，５−ジ−第３ブチル−４−ヒドロキシフェニルメチレン誘導体
EP0304493B1 (fr) Derives d'hydroxystyrene
RU2128165C1 (ru) Производные амидов и композиция, обладающая асат-ингибирующей активностью
RU2182905C2 (ru) Производные оксадиазола
US5143929A (en) 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
MXPA06008606A (es) Moduladores de transportadores con casete de union a atp.
PT699185E (pt) Derivados de guanidina inibidores da permuta na+/h+ nas celulas
CZ246394A3 (en) Quinoline derivatives as leukotriene antagonists, pharmaceutical preparations containing thereof and their use
EP0788490B1 (fr) Acides bisarylcarbinol cinnamiques comme inhibiteurs de la biosynthese des leucotrienes
US20040181075A1 (en) Process of making chalcone derivatives
EP0233461A2 (fr) 2-Pyrimidinamines substituées en 4,5 et 6
EP1419770A1 (fr) Agent d'acc l ration de l'expression de apo ai
JPS6316387B2 (fr)
NZ190512A (en) Hydantoin derivatives and pharmaceutical compositions
CA2132723A1 (fr) Derives de substitution pyridinique d'alcools benzyliques, antagonistes de la leucotriene
JP2004507501A (ja) ベンジリデンチアゾリジンジオンおよび抗真菌剤としてのそれらの使用
JP7012289B2 (ja) ベンゾイルグリシン誘導体およびその作製および使用の方法
US5202341A (en) Hydroxystyrene compounds having tyrosine kinase inhibiting activity
JP3086692B2 (ja) 抗炎症剤としてのフエナメート１，３，４‐チアジアゾール類および１，３，４‐オキサジアゾール類
US6495580B1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190129